Approval · Notice of Compliance 9151 · 2007
CO-CABERGOLINE: Notice of Compliance 9151
Issued November 1, 2007
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 9151
- Date
- November 1, 2007
- Company
- Cobalt Pharmaceuticals IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Therapeutic class
- Dopamine receptor agonist
- Canadian reference product
- DOSTINEX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CO-CABERGOLINE | 02301407 | Dormant |
Medicinal ingredients
- CABERGOLINE 0.5 MG per TAB